Experts in the field of gastrointestinal stromal tumors (GISTs) discuss the role of sequencing therapy in the frontline and later-line settings.
Advances in Later-Lines of Therapy for GIST
Fadi Braiteh, MD, discusses sequencing in patients with resectable and unresectable gastrointestinal stromal tumors (GISTs) and explains the impact on treatment considerations.
Considerations for gastrointestinal stromal tumor (GIST) sequencing in the adjuvant setting.
An overview of mutations in gastrointestinal stromal tumor (GIST) and how they can influence treatment selection.
Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss the current treatment options that are available for the treatment of gastrointestinal stromal tumor (GIST).
Implications for treating patients with gastrointestinal stromal tumors (GISTs) in the later lines of therapy after switching from 1 treatment to another.
Experts discuss the role of multidisciplinary management for patients with gastrointestinal stromal tumors (GISTs).
Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss unmet needs in the treatment of gastrointestinal stromal tumors (GISTs) and look to the future in terms of the evolving field.